Continuous mid-air 3-dimensional printing for pharmaceutical dosage forms
OwnerLeela Raghava Jaidev Chakka, Mohammed Maniruzzaman +2inventors
InventorsLeela Raghava Jaidev Chakka, Mohammed Maniruzzaman, Vineet R. Kulkarni, Faez Alkadi
Life of this patent
Estimating the term…
Abstract
Described are continuous manufacturing methods using 3D printing or any similar additive manufacturing technology to produce pharmaceutical dosage forms or pharmaceutical delivery devices. Manufacturing methods using hot-melt extrusion to fabricate filaments for fused deposition modeling (FDM) based 3D printing are disclosed. Methods using FDM based 3D printing to fabricate printed products suitable for pharmaceutical delivery purposes are disclosed. The printed products may have various shapes and configurations.
Claims40
A method of manufacturing a printed product, the method comprising:
- providing an initial mixture including at least one polymeric material and at least one active pharmaceutical ingredient (API);
- feeding the initial mixture into a heating barrel;
- heating the initial mixture to a temperature that reduces the viscosity of the at least one polymeric material;
- pumping the initial mixture through a die to form a filament;
- heating the filament to a fusing temperature;
- and
- depositing the filament on a receiving surface at an oblique angle to form a printed product.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of manufacturing a filament, the method comprising:
- providing an initial mixture including at least one polymeric material and at least one active pharmaceutical ingredient (API);
- feeding the initial mixture into a heating barrel;
- heating the initial mixture at a temperature that reduces the viscosity of the at least one polymeric material;
- and
- pumping the initial mixture through a die to form a filament.
(canceled)
(canceled)
A printed product comprising:
- at least one active pharmaceutical ingredient (API);
- and at least one polymeric material, wherein the printed product comprises a fused multilayer structure with one or more layers of the fused multilayer structure comprising the at least one active pharmaceutical ingredient (API) and the at least one polymeric material.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.